StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.23−0.39 (-0.92%)

Close on Nov 18, 2026Market cap $49.21BP/E 70.4Yield –

Teva Pharmaceutical Industries price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Teva Pharmaceutical Industries's price to sales ratio was 3.5× on Nov 10, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.5× to 3.5×, with a median of 1.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 20263.5×+1.4
2025Dec 31, 20252.1×+0.7
2024Dec 31, 20241.5×+0.7
2023Dec 29, 20230.8×+0.1
2022Dec 30, 20220.7×+0.1
2021Dec 31, 20210.5×−0.1
2020Dec 31, 20200.6×+0.0
2019Dec 31, 20190.6×−0.2
2018Dec 31, 20180.8×−0.7
2017Jan 31, 20171.5×−0.1
2016Dec 30, 20161.7×−1.2
2015Dec 31, 20152.8×+0.4
2014Dec 31, 20142.4×+0.7
2013Dec 31, 20131.7×+0.1
2012Dec 31, 20121.6×−0.5
2011Dec 30, 20112.1×−0.6
2010Dec 31, 20102.8×−1.2
2009Dec 31, 20094.0×–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?